title: Newer phosphodiesterase inhibitors: comparison with established agents.
abstract: Erectile dysfunction is defined as the consistent or recurrent inability to attain or maintain penile erection sufficient for sexual performance. Self-reported erectile dysfunction has increased significantly as men seek effective therapy, such as oral phosphodiesterase 5 inhibitors (PDE5i). PDE5i are now the drugs of choice in the initial therapy of erectile dysfunction. This review compares the currently available PDE5i with the second-generation PDE5i, which are soon to be available.
authors.affiliation: Division of Urology, Department of Surgery, Duke University Medical Center, Box 2374, Durham, NC 27710, USA.
authors.forename: Erin R
authors.initials: ER
authors.lastname: McNamara
authors.forename: Craig F
authors.initials: CF
authors.lastname: Donatucci
mesh_terms: D000284:Administration, Oral; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D010410:Penile Erection / Q000187:drug effects*; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*
chemical_list: D058986:Phosphodiesterase 5 Inhibitors